<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In vivo proton magnetic resonance spectroscopy is a safe and noninvasive tool that can be used to study aspects of brain chemistry and metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>This study was designed to evaluate its role in routine application to reveal the diagnostic reasons for <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHOD: 37 Alzheimer's disease patients (NINCDS-ADRDA criteria), 31 patients with subcortical ischemic vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (Chui et al </plain></SENT>
<SENT sid="3" pm="."><plain>criteria), and 13 subjects with subjective <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (<z:chebi fb="4" ids="38624">DSM</z:chebi>-IV criteria) were included in this retrospective study </plain></SENT>
<SENT sid="4" pm="."><plain>Magnetic resonance images were used for <z:mpath ids='MPATH_127'>atrophy</z:mpath> rating; additionally, proton magnetic resonance spectroscopy was performed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Significantly reduced N-acetylaspartate levels (p &lt;.05) were found in both patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and patients with subcortical ischemic vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> compared to the group with subjective memory complaints </plain></SENT>
<SENT sid="6" pm="."><plain>The ratios of N-acetylaspartate/<z:chebi fb="2" ids="16919">creatine</z:chebi> and N-acetylaspartate/<z:chebi fb="0" ids="17268">myo-inositol</z:chebi> were significantly lower in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> patients compared to patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (p =.012) or patients with subjective <z:hpo ids='HP_0002354'>memory impairment</z:hpo> (p =.002) </plain></SENT>
<SENT sid="7" pm="."><plain>N-acetylaspartate/<z:chebi fb="2" ids="16919">creatine</z:chebi> and N-acetylaspartate/<z:chebi fb="0" ids="17268">myo-inositol</z:chebi> ratios were positively correlated to the degree of <z:hpo ids='HP_0002059'>cerebral atrophy</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Disoriented patients displayed a low N-acetylaspartate/<z:chebi fb="2" ids="16919">creatine</z:chebi> ratio </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, we were not able to relate concurrent <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> or behavioral symptoms to any spectroscopic parameter </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: This study indicates that proton magnetic resonance spectroscopy parameters could provide additional information in differentiating between <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, subcortical ischemic vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, and subjective <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, this method can contribute to the routine diagnosis of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="C0851575" disease_type="Mental or Behavioral Dysfunction" abbrv="">Psychiatric and behavioral symptoms</z:e> associated with <z:hpo ids='HP_0000726'>dementia</z:hpo> or due to a major <z:e sem="disease" ids="C0004936" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychiatric disorder</z:e> cannot be related to changes in the measured proton magnetic resonance spectroscopy parameters </plain></SENT>
</text></document>